NO20051347L - eNOS-mutanter som er nyttige til genterapi. - Google Patents

eNOS-mutanter som er nyttige til genterapi.

Info

Publication number
NO20051347L
NO20051347L NO20051347A NO20051347A NO20051347L NO 20051347 L NO20051347 L NO 20051347L NO 20051347 A NO20051347 A NO 20051347A NO 20051347 A NO20051347 A NO 20051347A NO 20051347 L NO20051347 L NO 20051347L
Authority
NO
Norway
Prior art keywords
enos
polypeptide mutants
polypeptide
provides
amino acid
Prior art date
Application number
NO20051347A
Other languages
English (en)
Norwegian (no)
Inventor
Katalin Kauser
John Parkinson
Eric Blasko
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20051347L publication Critical patent/NO20051347L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • C12N9/0075—Nitric-oxide synthase (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
NO20051347A 2002-08-16 2005-03-15 eNOS-mutanter som er nyttige til genterapi. NO20051347L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40363802P 2002-08-16 2002-08-16
PCT/US2003/025745 WO2004016764A2 (fr) 2002-08-16 2003-08-15 Mutants d'enos utiles pour la therapie genique

Publications (1)

Publication Number Publication Date
NO20051347L true NO20051347L (no) 2005-04-28

Family

ID=31888260

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051347A NO20051347L (no) 2002-08-16 2005-03-15 eNOS-mutanter som er nyttige til genterapi.

Country Status (15)

Country Link
US (1) US20040096881A1 (fr)
EP (1) EP1553973A4 (fr)
JP (1) JP2005535345A (fr)
KR (1) KR20050042788A (fr)
CN (1) CN1691958A (fr)
AU (1) AU2003265461A1 (fr)
BR (1) BR0313511A (fr)
CA (1) CA2494847A1 (fr)
IL (1) IL166511A0 (fr)
MX (1) MXPA05001906A (fr)
NO (1) NO20051347L (fr)
PL (1) PL375219A1 (fr)
RU (1) RU2005107410A (fr)
WO (1) WO2004016764A2 (fr)
ZA (1) ZA200502183B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050074448A1 (en) * 2003-03-24 2005-04-07 The Curator Sof The University Of Missouri Method of treatment of endothelial dysfunction and engineered proteins for same
EP1708690B1 (fr) 2003-11-17 2016-07-20 BioMarin Pharmaceutical Inc. Traitement de la phénylcétonurie avec de la bh4
CA2842232C (fr) 2005-03-10 2015-01-27 Gen-Probe Incorporated Systemes et procedes permettant d'effectuer des dosages afin de detecter ou de quantifier des analytes dans des echantillons
US7739054B2 (en) * 2005-06-22 2010-06-15 Gen-Probe Incorporated Method and algorithm for quantifying polynucleotides
US10550178B2 (en) * 2010-03-18 2020-02-04 Srikanth Vedamoorthy Antibodies for detecting redox modulated proteins
US9439978B2 (en) 2011-09-29 2016-09-13 University Of South Florida Multilayered magnetic micelle compositions and methods for their use
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US9782494B2 (en) 2012-02-23 2017-10-10 University Of South Florida Methods of using multilayer magnetic micelle compositions
WO2013154771A1 (fr) * 2012-04-12 2013-10-17 Georgia Regents University Oxyde nitrique synthase résistant à l'oxydoréduction
CN106415562B (zh) * 2014-06-25 2019-12-10 国立研究开发法人科学技术振兴机构 膜蛋白质的热稳定化突变体预测装置、热稳定化突变体预测方法、以及程序
CN107802826B (zh) * 2017-10-26 2020-02-18 首都医科大学宣武医院 eNOS突变体在促进血管生成中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2369764A1 (fr) * 1999-04-16 2000-10-26 Yale University Mutations enos utiles en therapie genique et pour le criblage d'agents therapeutiques
US6620616B1 (en) * 2000-09-13 2003-09-16 The Cleveland Clinic Foundation Nucleic acids encoding nitric oxide synthase variants

Also Published As

Publication number Publication date
AU2003265461A1 (en) 2004-03-03
MXPA05001906A (es) 2005-04-28
EP1553973A2 (fr) 2005-07-20
ZA200502183B (en) 2006-09-27
JP2005535345A (ja) 2005-11-24
EP1553973A4 (fr) 2006-03-01
KR20050042788A (ko) 2005-05-10
RU2005107410A (ru) 2006-01-20
PL375219A1 (en) 2005-11-28
CN1691958A (zh) 2005-11-02
IL166511A0 (en) 2006-01-15
WO2004016764A3 (fr) 2005-05-19
US20040096881A1 (en) 2004-05-20
WO2004016764A2 (fr) 2004-02-26
CA2494847A1 (fr) 2004-02-26
BR0313511A (pt) 2006-06-13

Similar Documents

Publication Publication Date Title
NO20051347L (no) eNOS-mutanter som er nyttige til genterapi.
Haney et al. Structural basis for thermostability and identification of potential active site residues for adenylate kinases from the archaeal genus Methanococcus
Beckstein et al. Zipping and unzipping of adenylate kinase: atomistic insights into the ensemble of open↔ closed transitions
Lammens et al. Structural biochemistry of ATP-driven dimerization and DNA-stimulated activation of SMC ATPases
Bertrand et al. Crystal structure of UDP‐N‐acetylmuramoyl‐L‐alanine: D‐glutamate ligase from Escherichia coli
Zivanovic et al. Genome analysis and genome-wide proteomics of Thermococcus gammatolerans, the most radioresistant organism known amongst the Archaea
Tran et al. Crystal structure of the DpnM DNA adenine methyltransferase from the DpnII restriction system of Streptococcus pneumoniae bound to S-adenosylmethionine
WO2006116322A3 (fr) Compositions de nicotinamide riboside kinase et leurs methodes d'utilisation
Moorhead et al. The major myosin phosphatase in skeletal muscle is a complex between the β-isoform of protein phosphatase 1 and the MYPT2 gene product
NO20073808L (no) BCMA polypeptider og anvendelser derav
Vishwanath et al. Ribosomal protein-sequence block structure suggests complex prokaryotic evolution with implications for the origin of eukaryotes
Lee et al. Molecular modeling study of the editing active site of Escherichia coli leucyl‐tRNA synthetase: Two amino acid binding sites in the editing domain
Bujnicki et al. Identification of a bifunctional enzyme MnmC involved in the biosynthesis of a hypermodified uridine in the wobble position of tRNA
NO20055210L (no) Inhibitorproteiner av en protease og anvendelse derav
Purta et al. Sequence–structure–function relationships of a tRNA (m7G46) methyltransferase studied by homology modeling and site‐directed mutagenesis
Zahurancik et al. Comparison of the kinetic parameters of the truncated catalytic subunit and holoenzyme of human DNA polymerase ɛ
Paiardini et al. Threonine aldolase and alanine racemase: novel examples of convergent evolution in the superfamily of vitamin B6-dependent enzymes
Martin et al. Mapping of ATP binding regions in poly (A) polymerases by photoaffinity labeling and by mutational analysis identifies a domain conserved in many nucleotidyltransferases
Matsumoto et al. RNA recognition mechanism of eukaryote tRNA (m7G46) methyltransferase (Trm8–Trm82 complex)
Evans et al. NMR structure of the N-terminal domain of Saccharomyces cerevisiae RNase HI reveals a fold with a strong resemblance to the N-terminal domain of ribosomal protein L9
Wang et al. Mutations in the helix-turn-helix motif of the Escherichia coli UvrA protein eliminate its specificity for UV-damaged DNA.
Lin et al. Molecular analyses of an unusual translesion DNA polymerase from Methanosarcina acetivorans C2A
Braatz et al. An evaluation of molecular models of the cytochrome P450 Streptomyces griseolus enzymes P450SU1 and P450SU2
Wampler et al. Modeling the structure of pyrococcus furiosus rubredoxin by homology to other X‐ray structures
Wu et al. Interplay between primase and replication factor C in the hyperthermophilic archaeon Sulfolobus solfataricus

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application